Access through your institution

通过您的机构访问

Buy or subscribe

购买或订阅

Core binding factor acute myeloid leukemia (AML) defined by cytogenetic abnormalities of t(8;21)(q22;q22) and inv(16)(p13q22)/t(16;16)(p13;q22) [referred to as t(8;21) and inv(16) respectively] is classified as favorable risk by the ELN 2022 guidelines in the context of cytarabine-based intensive chemotherapy [1].

核心结合因子急性髓细胞白血病（AML）由t（8；21）（q22；q22）和inv（16）（p13q22）/t（16；16）（p13；q22）的细胞遗传学异常定义[分别称为t（8；21）和inv（16）]在基于阿糖胞苷的强化化疗背景下被ELN 2022指南归类为有利风险[1]。

Harboring either of these aberrations results in the formation of fusion genes, RUNX1-RUNX1T1 (or AML1/ETO) and CBFB-MYH11 respectively, that disrupt the function of core-binding factor (CBF) necessary for normal hematopoiesis [2]. Studies have shown complete remission (CR) rates of approximately 80–90% in adult CBF AML and allogeneic hematopoietic stem cell transplantation (alloHCT) is generally not recommended in first remission (CR1).

携带这些畸变中的任何一种都会导致融合基因RUNX1-RUNX1T1（或AML1/ETO）和CBFB-MYH11的形成，从而破坏正常造血所必需的核心结合因子（CBF）的功能。研究表明，成人CBF AML的完全缓解率（CR）约为80-90%，通常不建议在首次缓解（CR1）中进行异基因造血干细胞移植（alloHCT）。

Unfortunately, approximately 40–50% will eventually experience a relapse [3].The impact of concomitant mutations with CBF AML on outcomes has been of interest to refine prognostication. In particular, the presence of KIT mutations, found in approximately 25% of CBF AML patients, have been associated with higher relapse rates [4, 5].

不幸的是，大约40-50%最终会复发（3）。CBF AML伴随突变对结局的影响对于改善预后很有意义。特别是，在大约25%的CBF AML患者中发现的KIT突变的存在与较高的复发率有关[4，5]。

Marcucci et al. published their results that demonstrated that the addition of Dasatinib, a multi-kinase inhibitor with activity to KIT and SRC, to 7 + 3 and high-dose cytarabine consolidation yielded a CR rate of 90% with only a relapse rate of 16% in all patients with CBF AML [4]. In addition, the study produced 3-year disease free survival (DFS) and overall survival (OS) results of 75% and 77% respectively, with much better responses seen in younger patients with an age less than 60 years (79% and 85% for younger patients, and 60% and 51% for older patients).

Marcucci等人发表的研究结果表明，将达沙替尼（一种对KIT和SRC具有活性的多激酶抑制剂）添加到7 + 3和高剂量阿糖胞苷巩固治疗后，CR率为90%，所有CBF AML患者的复发率仅为16%[4]。此外，该研究产生的3年无病生存率（DFS）和总生存率（OS）结果分别为75%和77%，年龄小于60岁的年轻患者的反应要好得多（年轻患者分别为79%和85%，老年患者分别为60%和51%）。

KIT mutation was present in 11 out of 60 patients (19%) and was only able to show benefit in younger patients only when compared to wild-t.

60名患者中有11名（19%）存在KIT突变，只有与野生型t相比，才能在年轻患者中显示出益处。

This is a preview of subscription content, access via your institution

这是订阅内容的预览，可通过您的机构访问

Access options

访问选项

Access through your institution

通过您的机构访问

Access through your institution

通过您的机构访问

Change institution

变革机构

Buy or subscribe

购买或订阅

Subscribe to this journalReceive 12 print issues and online access251,40 € per yearonly 20,95 € per issueLearn moreBuy this articlePurchase on SpringerLinkInstant access to full article PDFBuy nowPrices may be subject to local taxes which are calculated during checkout

订阅本期刊每年可收到12期印刷版和在线访问251,40欧元每期仅20,95欧元了解更多在SpringerLink上购买本文立即访问全文PDFBuy NOW价格可能需要缴纳结帐时计算的当地税费

Additional access options:

其他访问选项：

Log in

登录

Learn about institutional subscriptions

Read our FAQs

阅读我们的常见问题

Contact customer support

联系客户支持

Data availability

数据可用性

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

在当前研究期间生成和/或分析的数据集可根据合理要求从通讯作者处获得。

ReferencesMrózek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman SP, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012;30:4515–23.Article

参考文献Mrózek K，Marcucci G，Nicolet D，Maharry KS，Becker H，Whitman SP等。欧洲白血病网标准化系统报告急性髓细胞白血病成人细胞遗传学和分子改变的预后意义。J临床肿瘤学。2012年；30:4515–23.文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Borthakur G, Kantarjian H. Core binding factor acute myelogenous leukemia-2021 treatment algorithm. Blood Cancer J. 2021;11:114.Article

Borthakur G，Kantarjian H.核心结合因子急性骨髓性白血病-2021治疗算法。血癌J.2021；11： 第114条

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23:5705–17.Article .

Marcucci G，Mrózek K，Ruppert AS，Maharry K，Kolitz JE，Moore JO等。t（8；21）的核心结合因子急性髓系白血病患者的预后因素和预后与inv（16）患者不同：癌症和白血病B组研究。J临床肿瘤学。2005年；23:5705-17。文章。

PubMed

PubMed

Google Scholar

谷歌学者

Marcucci G, Geyer S, Laumann K, Zhao W, Bucci D, Uy GL, et al. Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. Blood Adv. 2020;4:696–705.Article

Marcucci G，Geyer S，Laumann K，Zhao W，Bucci D，Uy GL等。达沙替尼联合化疗治疗先前未治疗的核心结合因子急性髓细胞白血病：CALGB 10801。血液Adv.2020；4： 696-705.文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Ishikawa Y, Kawashima N, Atsuta Y, Sugiura I, Sawa M, Dobashi N, et al. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. Blood Adv. 2020;4:66–75.Article

Ishikawa Y，Kawashima N，Atsuta Y，Sugiura I，Sawa M，Dobashi N等。KIT突变对RUNX1-RUNX1T1和CBFB-MYH11急性髓系白血病预后影响的前瞻性评估。血液Adv.2020；4： 66-75.文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

DeFilipp Z, Chen YB. How I treat with maintenance therapy after allogeneic HCT. Blood. 2023;141:39–48.Article

DeFilipp Z，Chen YB。同种异体HCT后我如何进行维持治疗。血。2023年；141:39–48.文章

PubMed

PubMed

Google Scholar

谷歌学者

Saini N, Marin D, Ledesma C, Delgado R, Rondon G, Popat UR, et al. Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL. Blood. 2020;136:1786–9.Article

Saini N，Marin D，Ledesma C，Delgado R，Rondon G，Popat UR等。TKIs异基因造血细胞移植后对费城染色体阳性ALL的影响。血。2020年；136:1786-9.文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, et al. BMT-CTN 1506/MORPHO Study Investigators. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3. J Clin Oncol. 2024;42:1766–75.Article

Levis MJ，Hamadani M，Logan B，Jones RJ，Singh AK，Litzow M等。BMT-CTN 1506/MORPHO研究调查员。Gilteritinib作为具有FLT3内部串联重复突变的AML的移植后维持。J临床肿瘤学。2024年；42:1766–75.文章

PubMed

PubMed

Google Scholar

谷歌学者

Fathi AT, Kim HT, Soiffer RJ, Levis MJ, Li S, Kim AS, et al. Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies. Blood Adv. 2022;6:5857–65.Article

Fathi AT，Kim HT，Soiffer RJ，Levis MJ，Li S，Kim AS等。异基因造血细胞移植治疗IDH2突变的髓系恶性肿瘤后，依那西地尼维持治疗。血液Adv.2022；6： 5857–65.文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Fathi AT, Kim HT, Soiffer RJ, Levis MJ, Li S, Kim AS, et al. Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia. Clin Cancer Res. 2023;29:2034–42.Article

Fathi AT，Kim HT，Soiffer RJ，Levis MJ，Li S，Kim AS等。异基因造血细胞移植治疗IDH1突变的急性髓细胞白血病后，伊沃西尼作为维持治疗的多中心I期试验。Clin Cancer Res.2023；

PubMed

PubMed

Google Scholar

谷歌学者

Zhou W, Chen G, Gong D, Gao Y, Yu L. Risk factors for post-transplant relapse and survival in younger adult patients with t(8;21)(q22;q22) acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: A multicenter retrospective study. Front Oncol. 2023;13:1138853.Article .

Zhou W，Chen G，Gong D，Gao Y，Yu L.接受异基因造血干细胞移植的t（8；21）（q22；q22）急性髓系白血病年轻成年患者移植后复发和生存的危险因素：一项多中心回顾性研究。前部Oncol。2023年；13： 1138853条。

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Halaburda K, Labopin M, Mailhol A, Socié G, Craddock C, Aljurf M, et al. Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Halaburda K，Labopin M，Mailhol A，SociéG，Craddock C，Aljurf M等。核心结合因子急性髓系白血病第二次完全缓解的异基因干细胞移植：欧洲血液和骨髓移植学会急性白血病工作组的一项研究。

Haematologica. 2020;105:1723–30.Article .

血液学。2020年；105:1723-30。文章。

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Download referencesAuthor informationAuthor notesThese authors contributed equally: Dat Ngo, Amanda BlackmonAuthors and AffiliationsDepartment of Pharmacy, City of Hope, Duarte, CA, USADat NgoDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USAAmanda Blackmon & Monzr M.

下载参考文献作者信息作者注意到这些作者做出了同样的贡献：Dat Ngo，Amanda BlackmonAuthors和附属机构加利福尼亚州杜阿尔特市希望之城药房部，USADat Ngo血液学和造血细胞移植部，加利福尼亚州杜阿尔特市，USAAmanda Blackmon＆Monzr M。

Al MalkiAuthorsDat NgoView author publicationsYou can also search for this author in.

Al MalkiAuthorsDat NgoView作者出版物您也可以在中搜索此作者。

PubMed Google ScholarAmanda BlackmonView author publicationsYou can also search for this author in

PubMed Google ScholarAmanda BlackmonView作者出版物您也可以在

PubMed Google ScholarMonzr M. Al MalkiView author publicationsYou can also search for this author in

PubMed Google ScholarMonzr M.Al MalkiView作者出版物您也可以在

PubMed Google ScholarContributionsDN was responsible for data extracting and reporting, preparation of manuscript. AB and MAL were responsible for concept design and editing of manuscript.Corresponding authorCorrespondence to

PubMed Google ScholarContributionsDN负责数据提取和报告，手稿的准备。AB和MAL负责手稿的概念设计和编辑。对应作者对应

Dat Ngo.Ethics declarations

我无处不在。伦理声明

Competing interests

相互竞争的利益

The authors declare no competing interests.

作者声明没有利益冲突。

Additional informationPublisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Rights and permissionsReprints and permissionsAbout this articleCite this articleNgo, D., Blackmon, A. & Al Malki, M.M. Dasatinib maintenance following allogeneic transplantation in acute myeloid leukemia with KIT mutation..

Additional informationPublisher的注释Springer Nature在已发布的地图和机构隶属关系中的管辖权主张方面保持中立。权利和许可关于本文的打印和许可引用本文NGO，D.，Blackmon，A。＆Al-Malki，M.M。达沙替尼在KIT突变的急性髓细胞白血病同种异体移植后的维持。。

Bone Marrow Transplant (2024). https://doi.org/10.1038/s41409-024-02425-wDownload citationReceived: 30 July 2024Revised: 16 September 2024Accepted: 18 September 2024Published: 08 October 2024DOI: https://doi.org/10.1038/s41409-024-02425-wShare this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard.

骨髓移植（2024）。https://doi.org/10.1038/s41409-024-02425-wDownload引文收到日期：2024年7月30日修订日期：2024年9月16日接受日期：2024年9月18日发布日期：2024年10月8日OI：https://doi.org/10.1038/s41409-024-02425-wShare本文与您共享以下链接的任何人都可以阅读此内容：获取可共享链接对不起，本文目前没有可共享的链接。复制到剪贴板。

Provided by the Springer Nature SharedIt content-sharing initiative

由Springer Nature SharedIt内容共享计划提供